Mefac (Mefenamic Acid)

Mefenamic acid blocks the activity of cyclooxygenase enzymes (COX‑1 and COX‑2), which are essential for producing prostaglandins. Prostaglandins promote inflammation, pain, and fever, so their reduction leads to decreased swelling, lower pain perception, and antipyretic effects.

The appropriate dose of Mefac is determined by the prescribing healthcare professional based on the individual’s condition, age, weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mefenamic acid in pregnancy and lactation are limited. It is generally advised to avoid use during the first trimester and to discuss potential risks with a healthcare provider. Breastfeeding mothers should also seek medical advice before taking the medication.

To request Mefac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mefac (mefenamic acid) is similar to other NSAIDs such as ibuprofen or naproxen in its mechanism of COX inhibition, but it may have a slightly higher risk of gastrointestinal side effects. Choice of NSAID often depends on patient tolerance, specific indication, and physician preference.

Mefac should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mefac is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce stomach irritation. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, hepatic injury, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice signs of bleeding, sudden kidney problems, or severe skin rashes.

Mefac is contraindicated in individuals with known hypersensitivity to mefenamic acid or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and patients who are in the third trimester of pregnancy. A healthcare professional should evaluate suitability before prescribing.